Estados Unidos - inglês - NLM (National Library of Medicine)

septodont, inc. - bupivacaine hydrochloride anhydrous (unii: aka908p8j1) (bupivacaine - unii:y8335394ro), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - marcaine® 0.5% (5 mg/ml) with epinephrine 1:200,000 injection is indicated for the production of local anesthesia for dental procedures by infiltration injection or nerve block in adults. marcaine® 0.5% (5 mg/ml) with epinephrine 1:200,000 injection is not recommended for children. marcaine® 0.5% (5 mg/ml) with epinephrine 1:200,000 injection, is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of bupivacaine solutions.

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 7.5 mg in 1 ml - marcaine spinal is indicated for subarachnoid injection in adults for the production of subarachnoid block (spinal anesthesia). marcaine spinal is contraindicated in: risk summary the available data on the use of marcaine spinal in pregnant women do not establish the presence or absence of developmental toxicity related to the use of marcaine spinal. in animal studies, embryo-fetal lethality was noted when bupivacaine was administered subcutaneously to pregnant rabbits during organogenesis and decreased pup survival was observed in a rat pre- and post-natal developmental study (dosing from implantation through weaning). these effects were observed at dose levels approximately 30 times the daily maximum recommended human dose (mrhd) on a body surface area (bsa) basis. based on animal data, advise pregnant women of the potential risk to a fetus (see data ). local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal

Estados Unidos - inglês - NLM (National Library of Medicine)

carestream health inc. - bupivacaine hydrochloride anhydrous (unii: aka908p8j1) (bupivacaine - unii:y8335394ro), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - marcaine® 0.5% with epineprhine 1:200,000 is indicated for the production of local anesthesia for dental procedures by infiltration injection or nerve block in adults. marcaine® 0.5% with epinephrine 1:200,000 is not recommended for children. marcaine® 0.5% with epinephrine 1:200,000, is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of bupivacaine solutions.

Estados Unidos - inglês - NLM (National Library of Medicine)

asclemed usa, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - bupivacaine hydrochloride injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. specific concentrations and presentations of bupivacaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see dosage and administration (2.2)]. limitations of use not all blocks are indicated for use with bupivacaine hydrochloride injection given clinically significant risks associated with use [see dosage and administration (2.2), contraindications (4), warnings and precautions (5.1, 5.5, 5.7, 5.9)] . bupivacaine hydrochloride injection is contraindicated in: - obstetrical paracervical block anesthesia. its use in this technique has resulted in fetal bradycardia and death. - intravenous regional anesthesia (bier block) [see w

Estados Unidos - inglês - NLM (National Library of Medicine)

asclemed usa, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - bupivacaine hydrochloride injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. specific concentrations and presentations of bupivacaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see dosage and administration (2.2)]. limitations of use not all blocks are indicated for use with bupivacaine hydrochloride injection given clinically significant risks associated with use [see dosage and administration (2.2), contraindications (4), warnings and precautions (5.1, 5.5, 5.7, 5.9)] . bupivacaine hydrochloride injection is contraindicated in: - obstetrical paracervical block anesthesia. its use in this technique has resulted in fetal bradycardia and death. - intravenous regional anesthesia (bier block) [see w

Israel - inglês - Ministry of Health

padagis israel agencies ltd, israel - bupivacaine hydrochloride - solution for injection - bupivacaine hydrochloride 5 mg/ml - bupivacaine - bupivacaine - long acting local anaesthetic.

Canadá - inglês - Health Canada

pfizer canada ulc - bupivacaine hydrochloride - solution - 15mg - bupivacaine hydrochloride 15mg - local anesthetics

Israel - inglês - Ministry of Health

padagis israel agencies ltd, israel - bupivacaine hydrochloride - solution for injection - bupivacaine hydrochloride 5 mg/ml - bupivacaine - bupivacaine - spinal anaesthesia for surgery, e.g. urological and lower limb surgery, lasting 2-3 hours, abdominal surgery lasting 45-60 minutes.

Israel - inglês - Ministry of Health

padagis israel agencies ltd, israel - bupivacaine hydrochloride - solution for injection - bupivacaine hydrochloride 5 mg/ml - bupivacaine - bupivacaine - spinal anaesthesia for surgery.

Estados Unidos - inglês - NLM (National Library of Medicine)

terrain pharmaceuticals - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 40 mg in 1 ml - where oral therapy is not feasible, injectable corticosteroid therapy, including kenalog-40 injection (triamcinolone acetonide injectable suspension, usp) is indicated for intramuscular use as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer,